Diabetic dyslipidaemiaBETTERIDGE, D. J.European journal of clinical investigation. Supplement. 1999, Vol 29, Num 2, pp 12-16, issn 0960-135XConference Paper

Lipids, diabetes, and vascular disease: the time to actBETTERIDGE, D. J.Diabetic medicine. 1989, Vol 6, Num 3, pp 195-218, issn 0742-3071Article

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetesBETTERIDGE, D. J; VERGES, B.Diabetologia (Berlin). 2005, Vol 48, Num 12, pp 2477-2481, issn 0012-186X, 5 p.Article

Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitusHENDRA, T; BETTERIDGE, D. J.Prostaglandins, leukotrienes and essential fatty acids. 1989, Vol 35, Num 4, pp 197-212, issn 0952-3278, 16 p.Article

Diabetic dyslipidemiaBETTERIDGE, D. J.The American journal of medicine. 1994, Vol 96, Num 6A, pp 6A.25-6A.31S, issn 0002-9343Conference Paper

The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetesBETTERIDGE, D. J.European heart journal supplements. 2004, Vol 6, Num G, pp G3-G7, issn 1520-765XConference Paper

Repaglinide : a new short-acting insulinotropic agent for the treatment of Type 2 diabetesOWENS, D. R.European journal of clinical investigation. Supplement. 1999, Vol 29, Num 2, pp 30-37, issn 0960-135XConference Paper

Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapyFEHER, M. D; BETTERIDGE, D. J.Cardiovascular drugs and therapy. 1989, Vol 3, pp 333-340, suppl.1Article

Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetesBETTERIDGE, D. J; GIBSON, J. M.Diabetic medicine. 2007, Vol 24, Num 5, pp 541-549, issn 0742-3071, 9 p.Article

Repaglinide, a new oral antidiabetic agent : a review of recent preclinical studiesMALAISSE, W. J.European journal of clinical investigation. Supplement. 1999, Vol 29, Num 2, pp 21-29, issn 0960-135XConference Paper

Diabetic dyslipidaemia: treatment implicationsBETTERIDGE, D. J.Journal of internal medicine. Supplement. 1994, Vol 236, Num 736, pp 47-52, issn 0955-7873Article

What is oxidative stress?BETTERIDGE, D. J.Metabolism, clinical and experimental. 2000, Vol 49, Num 2, pp 3-8, issn 0026-0495, SUP1Conference Paper

Prandial glucose regulation and cardiovascular disease in Type 2 diabetesKUUSISTO, J; LAAKSO, M.European journal of clinical investigation. Supplement. 1999, Vol 29, Num 2, pp 7-11, issn 0960-135XConference Paper

Lipids and thrombosisGASSER, J. A; BETTERIDGE, D. J.Baillière's clinical endocrinology and metabolism. 1990, Vol 4, Num 4, pp 923-938, issn 0950-351X, 16 p.Article

New approaches to managing multiple risk factors in cardiovascular diseaseERHARDT, L. R; BETTERIDGE, D. J.European heart journal supplements. 2004, Vol 6, Num G, issn 1520-765X, 19 p.Conference Proceedings

Glucose metabolism and the postprandial stateLEFEBVRE, P. J; SCHEEN, A. J.European journal of clinical investigation. Supplement. 1999, Vol 29, Num 2, pp 1-6, issn 0960-135XConference Paper

Implications of recent end-point trials on future management of hypertension and dyslipidaemiaDAHLÖF, B.European heart journal supplements. 2004, Vol 6, Num G, pp G13-G17, issn 1520-765XConference Paper

Collagen stimulation of intracellular calcium mobilization in washed platelets from patients with familial hypercholesterolaemiaCOOPER, M. B; TAN, K. C. B; BETTERIDGE, D. J et al.Biochemical Society transactions. 1991, Vol 19, Num 2, issn 0300-5127, p. 173SConference Paper

Effects of aspirin upon the flushing reaction induced by niceritrolJAY, R. H; DICKSON, A. C; BETTERIDGE, D. J et al.British journal of clinical pharmacology. 1990, Vol 29, Num 1, pp 120-122, issn 0306-5251Article

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisSCHERNTHANER, G; BARNETT, A. H; PIRAGS, V et al.Diabetologia (Berlin). 2010, Vol 53, Num 7, pp 1258-1269, issn 0012-186X, 12 p.Article

Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetesTAN, K. C. B; SHIU, S. W. M; CHOW, W. S et al.Diabetologia (Berlin). 2006, Vol 49, Num 11, pp 2756-2762, issn 0012-186X, 7 p.Article

Emerging insights into hypertension and dyslipidaemia synergiesSPOSITO, A. C.European heart journal supplements. 2004, Vol 6, Num G, pp G8-G12, issn 1520-765XConference Paper

Postprandial lipid metabolism and β-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat contentCOOPER, M. B; TAN, K. C. B; HALES, C. N et al.Diabetic medicine. 1996, Vol 13, Num 9, pp 816-827, issn 0742-3071Article

Management of hyperlipidaemia : guidelines of the British Hyperlipidaemia AssociationBETTERIDGE, D. J; DODSON, P. M; WINOCOUR, P. H et al.Postgraduate medical journal. 1993, Vol 69, Num 811, pp 359-369, issn 0032-5473Article

Withdrawal phenomena after atenolog and bopindolol : hormonal changes in normal volunteersWALDEN, R. J; TOMLINSON, B; GRAHAM, B et al.British journal of clinical pharmacology. 1990, Vol 30, Num 4, pp 547-556, issn 0306-5251, 10 p.Article